Showing 20 of 120 recruiting trials for “Small cell lung cancer”
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
👨⚕️ Revolution Medicines, Inc., Revolution Medicines, Inc.📍 16 sites📅 Started May 2022View details ↗
Alectinib Pharmacokinetic in Patients With NSCLC
👨⚕️ Oscar G Arrieta Rodriguez, M.D., M.Sc., Instituto Nacional de Cancerologia de Mexico📍 1 site📅 Started May 2022View details ↗
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
👨⚕️ Wang Wang Jie M.D., Peking University Cancer Hospital & Institute📍 27 sites📅 Started Apr 2022View details ↗
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
👨⚕️ Katherine Tkaczuk, MD, University of Maryland, Baltimore📍 1 site📅 Started Feb 2022View details ↗
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
👨⚕️ Iovance Biotherapeutics Study Team, Iovance Biotherapeutics📍 84 sites📅 Started May 2021View details ↗
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
👨⚕️ Mark Vincent, MD, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's📍 10 sites📅 Started Jan 2021View details ↗
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
RecruitingNCT04324164 ↗
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
RecruitingNCT04510129 ↗
A Multicenter Cancer Biospecimen Collection Study
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
👨⚕️ Mark P Dunphy, DO, Memorial Sloan Kettering Cancer Center📍 1 site📅 Started Dec 2019View details ↗
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
👨⚕️ Iovance Biotherapeutics Medical Monitor, Iovance Biotherapeutics📍 45 sites📅 Started May 2019View details ↗
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
👨⚕️ Steven A Rosenberg, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Sep 2018View details ↗
RecruitingNCT03774758 ↗
Biomarkers for Risk Stratification in Lung Cancer
👨⚕️ Mehrdad Arjomandi, M.D., University of California, San Francisco📍 3 sites📅 Started Dec 2017View details ↗
RecruitingNCT02146170 ↗
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
👨⚕️ Arjun Pennathur, MD, University of Pittsburgh Medical Center📍 1 site📅 Started Nov 2012View details ↗
← PreviousPage 6 of 6
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →